HomeCompareUCBJY vs ABBV

UCBJY vs ABBV: Dividend Comparison 2026

UCBJY yields 0.52% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.6K in total portfolio value
10 years
UCBJY
UCBJY
● Live price
0.52%
Share price
$150.79
Annual div
$0.79
5Y div CAGR
7.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.7K
Annual income
$111.23
Full UCBJY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — UCBJY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUCBJYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UCBJY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UCBJY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UCBJY
Annual income on $10K today (after 15% tax)
$44.56/yr
After 10yr DRIP, annual income (after tax)
$94.55/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,961.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UCBJY + ABBV for your $10,000?

UCBJY: 50%ABBV: 50%
100% ABBV50/50100% UCBJY
Portfolio after 10yr
$61.5K
Annual income
$12,441.49/yr
Blended yield
20.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

UCBJY
No analyst data
Altman Z
6.1
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UCBJY buys
1
ABBV buys
0
PoliticianChamberTickerTypeAmountDate
Daniel Goldman🏢 House$UCBJY▼ Sell$1,001 - $15,0002023-07-10
Daniel Goldman🏢 House$UCBJY▲ Buy$1,001 - $15,0002023-02-27
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUCBJYABBV
Forward yield0.52%3.06%
Annual dividend / share$0.79$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7.3%40.6%
Portfolio after 10y$20.7K$102.3K
Annual income after 10y$111.23$24,771.77
Total dividends collected$810.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: UCBJY vs ABBV ($10,000, DRIP)

YearUCBJY PortfolioUCBJY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,756$56.25$11,550$430.00$794.00ABBV
2$11,570$60.67$13,472$627.96$1.9KABBV
3$12,445$65.44$15,906$926.08$3.5KABBV
4$13,387$70.59$19,071$1,382.55$5.7KABBV
5$14,400$76.15$23,302$2,095.81$8.9KABBV
6$15,490$82.14$29,150$3,237.93$13.7KABBV
7$16,663$88.60$37,536$5,121.41$20.9KABBV
8$17,925$95.58$50,079$8,338.38$32.2KABBV
9$19,283$103.11$69,753$14,065.80$50.5KABBV
10$20,744$111.23$102,337$24,771.77$81.6KABBV

UCBJY vs ABBV: Complete Analysis 2026

UCBJYStock

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Full UCBJY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this UCBJY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UCBJY vs SCHDUCBJY vs JEPIUCBJY vs OUCBJY vs KOUCBJY vs MAINUCBJY vs JNJUCBJY vs MRKUCBJY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.